Now showing items 1-2 of 2

    • A phase I study of ABT-510 plus bevacizumab in advanced solid tumors. 

      Uronis, Hope E; Cushman, Stephanie M; Bendell, Johanna C; Blobe, Gerard C; Morse, Michael A; Nixon, Andrew B; Dellinger, Andrew; ... (13 authors) (Cancer Med, 2013-06)
      Targeting multiple regulators of tumor angiogenesis have the potential to improve treatment efficacy. Bevacizumab is a monoclonal antibody directed against vascular endothelial growth factor and ABT-510 is a synthetic analog ...
    • Principal-component-based multivariate regression for genetic association studies of metabolic syndrome components 

      Mei, Hao; Chen, Wei; Dellinger, Andrew; He, Jiang; Wang, Meng; Yau, Canddy; Srinivasan, Sathanur R; ... (8 authors) (2010)
      Background: Quantitative traits often underlie risk for complex diseases. For example, weight and body mass index (BMI) underlie the human abdominal obesity-metabolic syndrome. Many attempts have been made to identify ...